Immuno-Oncology
The development of immunotherapeutics has revolutionised treatment for cancer patients
Immunotherapies target the body's natural defences, the immune system, to fight cancer. Not all patients respond in the same way to immunotherapeutics and understanding the basis for these differences will inform treatment choice and lead to the development of more effective drugs.
Oxford Cancer
Learn more about Immuno-Oncology on the Oxford Cancer website
DEPARTMENTS IN THIS THEME
- Radcliffe Department of Medicine
- Nuffield Department of Clinical Medicine
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
- Department of Oncology
- Sir William Dunn School of Pathology
- Department of Biochemistry
Recent publications
Click here to view recent publications from this theme
LINKED THEMES
|
|
|
|
|
|
||
|
|
People in this Theme
-
Fiona Powrie FRS
Professor of Musculoskeletal Sciences and Director of the Kennedy Institute
-
Xin Lu
Professor of Cancer Biology, Director, Ludwig Institute for Cancer Research Oxford branch
-
Adrian Hill
Director of the Jenner Institute and Wellcome Trust Senior Investigator, Professor of Human Genetics and NIHR Senior Investigator
-
Audrey Gérard
Associate Professor
-
Peter Ratcliffe
Professor of Clinical Medicine, Director of the Target Discovery Institute
-
Mark Middleton
Head of Department of Oncology
-
Benoit van den Eynde
Professor of Tumour Immunology and Group Head / PI
-
Tao Dong
Professor of Immunology
-
Francesco Boccellato
Leadership Fellow
-
Lieping Chen
Visiting Professor in Cancer Immunotherapy
-
Nicola Ternette
Senior Scientist
-
Benjamin Fairfax
Professor of Cancer Immunogenetics
-
Kerry Fisher
Associate Professor
-
Eileen Parkes
Associate Professor, Innate tumour immunology
